Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Topiramate alone is not FDA-approved for weight loss. The FDA-approved version is phentermine-topiramate (sold as Qsymia), a fixed-dose combination capsule.
- In the CONQUER and EQUIP trials, the highest-dose phentermine-topiramate combo produced 9-10% average weight loss at one year (Gadde et al., Lancet 2011; Allison et al., Obesity 2012).
- Topiramate by itself is sometimes prescribed off-label for weight loss at doses of 25-200 mg per day, with average loss of 5-7% over 6-12 months (Verrotti et al., Obes Rev 2011).
- Common side effects include tingling in the hands and feet, taste changes (especially with carbonated drinks), word-finding trouble, and slowed thinking.
- GLP-1 medications produce roughly 15-22% average weight loss in clinical trials, meaningfully more than topiramate. The two work through different mechanisms and are sometimes combined under specialist care.
Direct answer (40-60 words)
Topiramate is an anticonvulsant that produces 5-7% average weight loss when used off-label, or 9-10% when combined with phentermine in the FDA-approved Qsymia capsule (Gadde et al., Lancet 2011). It works by blunting appetite and reducing food reward signals. GLP-1 medications produce more weight loss but cost more.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What topiramate is and why it causes weight loss
- Is topiramate FDA-approved for weight loss?
- How much weight people lose on topiramate
- Typical doses for off-label weight loss
- Phentermine-topiramate (Qsymia): the FDA-approved version
- Side effects you should know about
- Who should not take topiramate
- Topiramate vs GLP-1 medications
- Drug interactions and screening labs
- How long does it take to work
- What happens when you stop
- Cost and insurance coverage
- FAQ
- Sources
- Footer disclaimers
- Article and FAQ schema
What topiramate is and why it causes weight loss
Topiramate (brand name Topamax) is an anticonvulsant medication. It's been on the market since 1996 for epilepsy and migraine prevention. The weight loss effect was noticed almost immediately in clinical use. Patients on topiramate for seizures kept losing weight without trying.
The mechanism isn't one single thing. Researchers believe topiramate works through several overlapping pathways:
- It enhances GABA activity in the brain. GABA is the main inhibitory neurotransmitter, and stronger GABA signaling appears to reduce the reward value of food.
- It blocks certain glutamate receptors. Glutamate drives reward and craving signals. Blocking it dulls the urge to eat for pleasure.
- It inhibits carbonic anhydrase. This causes mild taste changes (especially with sodas and beer) and is part of why some patients feel less interested in eating.
- It may slow stomach emptying somewhat, although this is a smaller effect than GLP-1 medications produce.
The net result is that people on topiramate often eat less, feel full sooner, and lose interest in foods they used to crave. They don't experience the dramatic appetite suppression of a GLP-1, but the change is real and measurable.
Is topiramate FDA-approved for weight loss?
Topiramate by itself is not FDA-approved for weight loss. The FDA-approved indications for topiramate monotherapy are:
- Partial-onset seizures (epilepsy), as monotherapy or add-on
- Primary generalized tonic-clonic seizures
- Lennox-Gastaut syndrome (add-on)
- Migraine prevention in adults
The FDA-approved weight-loss product that contains topiramate is phentermine-topiramate extended-release, sold as Qsymia. Qsymia was approved in July 2012 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition like type 2 diabetes, hypertension, or dyslipidemia (FDA Qsymia label, 2012, updated 2023).
When clinicians prescribe topiramate alone for weight loss, that's an off-label use. Off-label prescribing is legal and common, but it means the FDA hasn't reviewed topiramate alone for weight-loss safety and efficacy at the doses commonly used. Insurance often won't cover off-label topiramate for weight loss for the same reason.
How much weight people lose on topiramate
The clinical evidence breaks into two buckets: topiramate alone and phentermine-topiramate combination.
Topiramate alone, off-label, in obesity trials:
A 2011 systematic review pooled 10 randomized trials of topiramate monotherapy in adults with obesity (Verrotti et al., Obes Rev 2011). Across the trials, average weight loss ranged from 5.0% to 7.6% at 6 to 12 months on doses of 64 mg to 192 mg per day. Placebo arms lost about 1-2% over the same period.
A 2003 trial by Bray and colleagues randomized 385 adults with obesity to topiramate or placebo for 24 weeks. The 192 mg group lost 6.3% of starting weight, and the 256 mg group lost 6.6%, both meaningfully more than placebo (Bray et al., Obes Res 2003). The trial was stopped early because dropout rates were high due to neurocognitive side effects.
Phentermine-topiramate combination, FDA-approved:
The CONQUER trial (Gadde et al., Lancet 2011) randomized 2,487 adults with obesity and at least two cardiometabolic risk factors. After one year:
- Placebo: 1.4% loss
- Mid-dose phentermine 7.5 mg / topiramate 46 mg: 7.8% loss
- High-dose phentermine 15 mg / topiramate 92 mg: 9.8% loss
The EQUIP trial in adults with class II or III obesity reported similar numbers, with the high-dose group losing 10.9% over a year (Allison et al., Obesity 2012).
So roughly: topiramate alone gives you 5-7%, and the combo gives you 8-10%. For context, the SURMOUNT-1 trial of tirzepatide reported an average 20.9% loss at the highest dose at week 72 (Jastreboff et al., NEJM 2022).
Typical doses for off-label weight loss
When clinicians prescribe topiramate alone for weight loss, they almost always start low and go slow. The reason is that side effects like word-finding difficulty and tingling are dose-related and tend to fade with slow titration.
A common off-label schedule looks like this:
| Week | Dose |
|---|---|
| 1-2 | 25 mg at bedtime |
| 3-4 | 50 mg at bedtime |
| 5-6 | 50 mg morning, 50 mg evening (100 mg total) |
| 7-8 | 50 mg morning, 100 mg evening (150 mg total) |
| 9+ | 100 mg morning, 100 mg evening (200 mg total) |
Most weight-loss benefit shows up between 100 and 200 mg per day. Pushing higher doses doesn't reliably produce more weight loss but does produce more side effects (Bray et al., Obes Res 2003).
For migraine prevention, the typical dose is 100 mg per day. Many migraine patients lose modest weight as a side effect at that dose without specifically being treated for obesity.
Phentermine-topiramate (Qsymia): the FDA-approved version
Qsymia is a once-daily extended-release capsule that combines two medications:
- Phentermine: a sympathomimetic that suppresses appetite (related to amphetamines, but milder)
- Topiramate ER: the same anticonvulsant we've been discussing, in extended-release form
The dose options are:
| Strength | Phentermine | Topiramate ER |
|---|---|---|
| Starting (3.75/23 mg) | 3.75 mg | 23 mg |
| Recommended (7.5/46 mg) | 7.5 mg | 46 mg |
| Titration (11.25/69 mg) | 11.25 mg | 69 mg |
| Top dose (15/92 mg) | 15 mg | 92 mg |
The standard schedule is to start at 3.75/23 mg for two weeks, increase to 7.5/46 mg, hold there for 12 weeks, and assess. If weight loss is less than 3% by week 12, the FDA label says to either stop or step up to 11.25/69 mg for two weeks, then 15/92 mg.
Why combine the two drugs? Phentermine works on a fast time scale (appetite suppression within hours, mostly through norepinephrine release), and topiramate works on a slower time scale (reduced food reward, mild taste changes, dampened cravings). Combining them in low doses gets a bigger effect with fewer side effects than either drug at a high dose alone.
Pregnancy warning. Phentermine-topiramate is contraindicated in pregnancy. Topiramate increases the risk of cleft lip and cleft palate in babies exposed during the first trimester (Hernandez-Diaz et al., Neurology 2012). Female patients of reproductive age must use reliable contraception and have a negative pregnancy test before starting and monthly during treatment.
Side effects you should know about
Topiramate has a distinct side-effect profile that some patients tolerate easily and others can't stand. The most common side effects from clinical trials and post-marketing data:
Common (10% or more):
- Paresthesias (tingling, often in hands, feet, or face)
- Taste changes, especially with carbonated drinks (which can taste flat or metallic)
- Decreased appetite (which is the point, but some patients lose too much)
- Difficulty concentrating or word-finding trouble
- Fatigue or drowsiness
- Dizziness
Less common but serious:
- Acute angle-closure glaucoma. This is a true emergency. Symptoms are sudden eye pain, blurred vision, and headache, usually in the first month. Stop the drug and get to an emergency room.
- Kidney stones. Topiramate increases risk roughly 2-fold. Drink plenty of water (at least 2 liters per day) to reduce risk.
- Metabolic acidosis (low blood bicarbonate). Usually mild but can be significant at high doses. Some clinicians check labs at baseline and periodically.
- Hyperthermia and decreased sweating. Less common but worth knowing if you exercise in heat.
- Mood changes, including depression and rarely suicidal thinking. The FDA added a class warning to all anticonvulsants in 2008 (FDA antiepileptic drug class label, 2008).
The cognitive side effect deserves its own note. Patients often describe it as "topamax brain" or feeling foggy. Word-finding difficulty (knowing what you mean but not being able to retrieve the word) is the classic complaint. It's reversible when the drug is stopped, but for some patients (writers, lawyers, students, public speakers) it's the deal-breaker. Slow titration helps, and many patients adapt over 4-8 weeks.
Who should not take topiramate
Topiramate is not appropriate for everyone. Absolute contraindications include:
- Pregnancy (cleft lip/palate risk)
- History of acute angle-closure glaucoma
- Known hypersensitivity to topiramate
- Recent alcohol use within 6 hours of dosing (extended-release forms)
Relative contraindications and cautions:
- History of kidney stones (the drug roughly doubles the risk)
- Chronic kidney disease (dose adjustments needed at eGFR below 70)
- Hepatic impairment (dose adjustment needed)
- Concurrent use of carbonic anhydrase inhibitors (acetazolamide, zonisamide), which compound the metabolic acidosis risk
- History of severe depression or suicidal ideation
- Concurrent use of medications that lower bicarbonate
- Patients on a ketogenic diet (compounds the acidosis risk)
For weight-loss prescribing specifically, age below 18 (limited data outside of seizure use), pregnancy planning, and patients whose work requires fast verbal recall and word retrieval are situations where another medication is usually a better choice.
Topiramate vs GLP-1 medications
This is the question most patients want answered: should I try topiramate, or should I go straight to a GLP-1?
| Factor | Topiramate alone | Phentermine-topiramate (Qsymia) | GLP-1 (semaglutide/tirzepatide) |
|---|---|---|---|
| Average 1-year weight loss | 5-7% | 9-11% | 15-22% |
| FDA-approved for weight loss | No (off-label) | Yes | Yes (Wegovy, Zepbound) |
| Route | Oral capsule | Oral capsule | Weekly subcutaneous injection |
| Cash price (no insurance) | $25-80/month generic | $200-300/month | $179-1,300/month depending on product |
| Most common side effects | Tingling, taste changes, brain fog | Same plus heart-rate increase | Nausea, constipation |
| Pregnancy | Contraindicated | Contraindicated | Contraindicated |
| Reversibility on stopping | Most weight regains within 1 year | Most weight regains within 1 year | Most weight regains within 1 year |
The bottom line: GLP-1s produce more weight loss on average, but they cost more, require injections, and cause GI side effects that some patients can't tolerate. Topiramate (alone or as Qsymia) is cheaper, oral, and works well enough for moderate weight-loss goals, but the cognitive side effects are limiting for many people.
For some patients with a strong cravings component (binge eating, food noise, alcohol urges), topiramate can be a useful add-on to a GLP-1 under specialist supervision. The combination isn't FDA-approved and should only be considered with a clinician who's comfortable managing both drugs.
[Internal link to /articles/medications/glp-1-vs-other-weight-loss-drugs/]
Drug interactions and screening labs
Topiramate interacts with several common medications:
- Oral contraceptives. Topiramate can reduce the effectiveness of estrogen-based birth control at doses above 200 mg per day. At lower weight-loss doses, the effect is smaller but real. Use a backup method or a higher-estrogen pill.
- Carbonic anhydrase inhibitors (acetazolamide, zonisamide, methazolamide): compound metabolic acidosis. Avoid combining.
- CNS depressants (alcohol, benzodiazepines, opioids, gabapentin): added drowsiness and cognitive slowing.
- Lithium: levels can rise. Monitor.
- Phenytoin and carbamazepine: these reduce topiramate levels. Topiramate dose may need to be higher.
- Metformin: topiramate slightly raises metformin levels. Usually clinically insignificant.
- Hydrochlorothiazide and other diuretics: can compound metabolic acidosis and electrolyte shifts.
Baseline labs most clinicians order before starting topiramate for weight loss:
- Comprehensive metabolic panel (creatinine, eGFR, bicarbonate, liver enzymes)
- Pregnancy test in females of reproductive age
- TSH (to screen for thyroid causes of weight gain or weight loss)
- A1c if there's a diabetes risk
Repeat labs at 3-6 months are reasonable, especially the bicarbonate level and kidney function.
How long does it take to work
Most patients notice appetite changes and food-craving differences within 2-4 weeks of reaching a therapeutic dose (around 100 mg per day). Measurable weight loss usually appears between weeks 4 and 12.
The FDA label for Qsymia recommends an early-response check at 12 weeks. If you've lost less than 3% of starting weight at 12 weeks on the recommended dose, the medication is unlikely to produce meaningful long-term loss for you. Either step up the dose or switch.
For off-label topiramate alone, the same logic applies: if you've titrated to 100-200 mg per day and haven't lost at least 3-5% by month 3, it's reasonable to discuss other options with your clinician.
What happens when you stop
Most patients regain weight after stopping topiramate. The CONQUER and EQUIP follow-up data showed that patients who discontinued phentermine-topiramate at one year regained 50-70% of lost weight within the next 12 months (Garvey et al., Am J Clin Nutr 2012).
This isn't a topiramate problem. It's an obesity-medicine problem. Obesity is a chronic disease, and stopping any pharmacotherapy (topiramate, phentermine-topiramate, GLP-1, naltrexone-bupropion) typically results in weight regain unless lifestyle factors have been substantially modified during the treatment period.
Tapering matters. Don't stop topiramate cold turkey, especially at higher doses. Sudden discontinuation can trigger seizures even in patients without a seizure history. The standard taper is to reduce the dose by 25-50 mg every 1-2 weeks until off.
Cost and insurance coverage
Topiramate alone (generic):
- 25 mg, 50 mg, 100 mg, 200 mg tablets all have inexpensive generics
- Cash price with GoodRx: $4-30 per month
- Most insurance plans cover topiramate at Tier 1 ($5-15 copay) for FDA-approved indications (epilepsy, migraine)
- For off-label weight-loss use, many plans deny coverage. The workaround is paying the cash price, which is low for generic topiramate.
Phentermine-topiramate (Qsymia):
- No generic available as of 2026
- Cash price: $200-300 per month at major chains
- Insurance coverage varies. Many commercial plans cover it with prior authorization for patients meeting BMI criteria.
- Manufacturer savings programs can reduce commercial-insurance copays substantially. Cash-pay programs through the manufacturer are also available at around $100 per month.
Compounded options:
Compounded semaglutide and compounded tirzepatide are available through telehealth platforms at $179-279 per month. They're not FDA-approved and not equivalent to brand-name products, but for patients who want injectable GLP-1 therapy without insurance, they're often the most affordable option.
[Internal link to /articles/cost/glp-1-without-insurance/]
FAQ
Does topiramate cause weight loss in everyone? No. About 60-70% of patients lose at least 5% of starting weight on topiramate at therapeutic doses. The rest see little or no change. If you haven't lost at least 3% by 3 months on a stable dose, the drug is unlikely to produce meaningful long-term loss for you.
How much weight will I lose on topiramate alone? On average, 5-7% of starting body weight over 6-12 months on doses of 100-200 mg per day (Verrotti et al., Obes Rev 2011). For a 200-pound person, that's 10-14 pounds. Some patients lose substantially more, and some lose nothing.
Is topiramate the same as phentermine? No. They're two different drugs with different mechanisms. Phentermine is a sympathomimetic that releases norepinephrine and suppresses appetite. Topiramate is an anticonvulsant that affects GABA, glutamate, and carbonic anhydrase. They're combined in Qsymia precisely because their mechanisms are complementary.
Can I take topiramate with a GLP-1? Possibly, under specialist supervision. The combination isn't FDA-approved or studied in large trials, but some obesity clinicians prescribe both for patients with strong cravings or food noise on top of their GLP-1 therapy. Discuss with a clinician familiar with both medications.
Does topiramate cause hair loss? Yes, in a small percentage of patients (about 1-3% in seizure trials). The hair loss is usually diffuse, mild, and reversible when the drug is stopped or the dose is lowered. It's listed in the prescribing information as a known but uncommon adverse effect.
Does topiramate cause kidney stones? Yes, it roughly doubles the risk of kidney stones compared to placebo (Welch et al., Epilepsia 2006). Drinking 2 liters of water per day, limiting sodium, and getting a baseline urinalysis if you have a stone history all reduce risk. The stone type is usually calcium phosphate, related to the metabolic acidosis topiramate causes.
How fast does topiramate work for weight loss? Appetite changes are usually noticeable within 2-4 weeks of reaching a therapeutic dose. Measurable weight loss typically appears between weeks 4 and 12. The 12-week mark is the standard early-response checkpoint.
Is the brain fog permanent? No. The cognitive side effects of topiramate are reversible. Most patients return to baseline within 2-4 weeks of stopping the drug. Some patients adapt to the side effect over the first 1-2 months on the drug and find it fades on its own.
Can I drink alcohol on topiramate? Light social drinking is generally not contraindicated with regular topiramate, but alcohol increases the cognitive side effects and the risk of dehydration. With phentermine-topiramate (Qsymia), alcohol within 6 hours of dosing is contraindicated because of the extended-release formulation.
Is topiramate safe long-term? For its FDA-approved indications (seizures, migraine), topiramate has 25+ years of post-marketing data and is considered safe for long-term use with monitoring. For off-label weight-loss use, the longest trial data extend to 2 years for phentermine-topiramate. Beyond that, long-term safety is extrapolated from seizure-treatment data.
Does insurance cover topiramate for weight loss? Generic topiramate is usually covered cheaply for seizures and migraine. For off-label weight-loss use, many insurance plans deny coverage. The cash price for generic topiramate is low enough (often under $20 per month) that this isn't a major barrier. For Qsymia, many commercial plans cover it with prior authorization.
Should I try topiramate before a GLP-1? There's no universal answer. GLP-1s produce more weight loss but cost more and require injections. Topiramate is cheaper and oral but produces less loss and has cognitive side effects. The right starting point depends on your weight-loss goal, budget, side-effect tolerance, and other medical conditions. A clinician should help you decide.
Sources
- Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
- Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330-342.
- Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL). Am J Clin Nutr. 2012;95(2):297-308.
- Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722-733.
- Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss: a review. Obes Rev. 2011;12(5):e338-e347.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- U.S. Food and Drug Administration. Qsymia (phentermine and topiramate extended-release) capsules prescribing information. Initial approval 2012, updated 2023.
- Welch BJ, Graybeal D, Moe OW, et al. Biochemical and stone-risk profiles with topiramate treatment. Epilepsia. 2006;47(7):1187-1191.
- Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692-1699.
- U.S. Food and Drug Administration. Antiepileptic drugs and suicidality (FDA class label warning). 2008.
- Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA. 2016;315(22):2424-2434.
- Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription Medications to Treat Overweight and Obesity. Updated 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Topamax, Qsymia, Ozempic, Wegovy, Zepbound, and Mounjaro are registered trademarks of their respective owners (Janssen, Vivus/Sheratan, Novo Nordisk A/S, Eli Lilly). FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Related FormBlends Guides
These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:
- GLP-1 For Weight Loss: Complete Guide 2026
- GLP-1 Online Prescription: Complete Guide 2026
- Topiramate for Weight Loss: How Much It Works, the Dosing, and Where It Fits Next to GLP-1 Medications
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →